# Humacyte, Inc.: overview HUMA · Nasdaq · CIK 1818382 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/huma.md) · [Financials](/companies/huma/financials.md) · [Filings](/companies/huma/filings.md) · [Insiders](/companies/huma/insiders.md) Latest reported revenue: [$406.0k](/filings/0001193125-26-347022.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 12, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-347022). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.0](/filings/0001818382-25-000132.md) | [0.0 d](/filings/0001818382-26-000004.md) | [0.5](/filings/0001193125-26-221755.md) | [0.3](/filings/0001193125-26-347022.md) | [0.8](/filings/0001818382-25-000132.md) | [0.5 d](/filings/0001818382-26-000004.md) | [0.5](/filings/0001193125-26-221755.md) | [0.4](/filings/0001193125-26-347022.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | [(4484.3%)](/filings/0001193125-26-221755.md) | [(9876.1%)](/filings/0001193125-26-347022.md) | [(3239.0%)](/filings/0001818382-25-000132.md) | [(6603.0%) d](/filings/0001818382-26-000004.md) | [(5845.5%)](/filings/0001193125-26-221755.md) | [(6649.3%)](/filings/0001193125-26-347022.md) | | Net margin | % | not reported | not reported | [7570.4%](/filings/0001193125-26-347022.md) | [(12511.0%)](/filings/0001193125-26-347022.md) | [(2325.4%)](/filings/0001818382-25-000132.md) | [(5311.3%) d](/filings/0001818382-26-000004.md) | [(3559.4%)](/filings/0001193125-26-347022.md) | [(9064.5%)](/filings/0001193125-26-347022.md) | | Diluted EPS | $ per share | [(0.33)](/filings/0001818382-25-000132.md) | not reported | [0.28](/filings/0001193125-26-221755.md) | [(0.24)](/filings/0001193125-26-347022.md) | [(0.11)](/filings/0001818382-25-000132.md) | not reported | [(0.09)](/filings/0001193125-26-221755.md) | [(0.16)](/filings/0001193125-26-347022.md) | | Free cash flow | $m | [(23.8) d](/filings/0001818382-25-000132.md) | [(26.6) d](/filings/0001818382-26-000004.md) | [(28.8)](/filings/0001193125-26-221755.md) | [(27.0) d](/filings/0001193125-26-347022.md) | [(24.0) d](/filings/0001818382-25-000132.md) | [(26.2) d](/filings/0001818382-26-000004.md) | [(25.3)](/filings/0001193125-26-221755.md) | [(22.2) d](/filings/0001193125-26-347022.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | [0.0](/filings/0001818382-26-000004.md) | [2.0](/filings/0001818382-26-000004.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | [(5306.0%)](/filings/0001818382-26-000004.md) | | Net margin | % | not reported | not reported | not reported | not reported | [(2003.6%)](/filings/0001818382-26-000004.md) | | Diluted EPS | $ per share | [(0.66)](/filings/0001818382-23-000016.md) | [(0.12)](/filings/0001818382-24-000040.md) | [(1.07)](/filings/0001818382-25-000034.md) | [(1.26)](/filings/0001818382-26-000004.md) | [(0.26)](/filings/0001818382-26-000004.md) | | Free cash flow | $m | [(81.4)](/filings/0001818382-23-000016.md) | [(72.2)](/filings/0001818382-24-000040.md) | [(75.6)](/filings/0001818382-25-000034.md) | [(99.7)](/filings/0001818382-26-000004.md) | [(106)](/filings/0001818382-26-000004.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/huma/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [ANTIPODES PARTNERS Ltd](/funds/1652442.md) | 2026-06-30 | $7.9m | 10,103,647 | | Added +4,379,897 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $7.9m | 10,107,679 | | Added +2,949,517 | | [Alyeska Investment Group, L.P.](/funds/1453072.md) | 2026-06-30 | $4.7m | 6,022,925 | | New +6,022,925 | | [Davidson Kempner Capital Management LP](/funds/1595082.md) | 2026-06-30 | $3.9m | 5,000,000 | | New +5,000,000 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $3.8m | 4,839,929 | | Reduced −7,477,026 | | [GREAT POINT PARTNERS LLC](/funds/1281446.md) | 2026-06-30 | $2.9m | 3,750,000 | | Unchanged | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $2.2m | 2,843,493 | | Added +61,423 | | [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $2.0m | 2,597,134 | | Added +672,443 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $1.7m | 2,185,225 | | Reduced −1,472,883 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $1.5m | 1,909,049 | | Added +1,800,895 | ## Recent filings [All 501 filings](/companies/huma/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-28 | 20:05 ET | [8-K](/filings/0001818382-26-000011.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001818382-26-000011 | | 2026-08-18 | 13:15 ET | [SCHEDULE 13D/A](/filings/0001104659-26-098152.md) | Ownership report, active investor, amended | 0001104659-26-098152 | | 2026-08-12 | 20:45 ET | [10-Q](/filings/0001193125-26-347022.md) | Quarterly report, period 2026-06-30 | 0001193125-26-347022 | | 2026-08-12 | 11:03 ET | [8-K](/filings/0001104659-26-094440.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-094440 | | 2026-07-31 | 21:00 ET | [8-K](/filings/0001104659-26-089281.md) | 3.01 Delisting notice | 0001104659-26-089281 | | 2026-07-13 | 21:25 ET | [SCHEDULE 13D/A](/filings/0001104659-26-083164.md) | Ownership report, active investor, amended | 0001104659-26-083164 | | 2026-06-15 | 13:53 ET | [SCHEDULE 13D/A](/filings/0001104659-26-073827.md) | Ownership report, active investor, amended | 0001104659-26-073827 | | 2026-06-11 | 20:43 ET | [8-K](/filings/0001104659-26-072980.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-072980 | | 2026-06-10 | 20:34 ET | [8-K](/filings/0001104659-26-072382.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-072382 | | 2026-06-09 | 20:30 ET | [8-K](/filings/0001104659-26-071862.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001104659-26-071862 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001818382-26-000004.md), filed Mar 27, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/28d5eb0c-efcc-4a88-a9cd-e88484275d30) ## About the filer - CIK: 1818382 - Tickers: HUMA - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.